Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice

Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient’s own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages a...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yunsik, Lee, Sanghyuk, Kim, Kapyoul, Kim, Soo-Hyun, Chung, Yeun-Jun, Lee, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082857/
https://www.ncbi.nlm.nih.gov/pubmed/30089794
http://dx.doi.org/10.1038/s12276-018-0115-0
_version_ 1783345860947476480
author Choi, Yunsik
Lee, Sanghyuk
Kim, Kapyoul
Kim, Soo-Hyun
Chung, Yeun-Jun
Lee, Charles
author_facet Choi, Yunsik
Lee, Sanghyuk
Kim, Kapyoul
Kim, Soo-Hyun
Chung, Yeun-Jun
Lee, Charles
author_sort Choi, Yunsik
collection PubMed
description Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient’s own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.
format Online
Article
Text
id pubmed-6082857
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60828572018-08-17 Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice Choi, Yunsik Lee, Sanghyuk Kim, Kapyoul Kim, Soo-Hyun Chung, Yeun-Jun Lee, Charles Exp Mol Med Review Article Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient’s own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies. Nature Publishing Group UK 2018-08-07 /pmc/articles/PMC6082857/ /pubmed/30089794 http://dx.doi.org/10.1038/s12276-018-0115-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Choi, Yunsik
Lee, Sanghyuk
Kim, Kapyoul
Kim, Soo-Hyun
Chung, Yeun-Jun
Lee, Charles
Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
title Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
title_full Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
title_fullStr Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
title_full_unstemmed Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
title_short Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
title_sort studying cancer immunotherapy using patient-derived xenografts (pdxs) in humanized mice
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082857/
https://www.ncbi.nlm.nih.gov/pubmed/30089794
http://dx.doi.org/10.1038/s12276-018-0115-0
work_keys_str_mv AT choiyunsik studyingcancerimmunotherapyusingpatientderivedxenograftspdxsinhumanizedmice
AT leesanghyuk studyingcancerimmunotherapyusingpatientderivedxenograftspdxsinhumanizedmice
AT kimkapyoul studyingcancerimmunotherapyusingpatientderivedxenograftspdxsinhumanizedmice
AT kimsoohyun studyingcancerimmunotherapyusingpatientderivedxenograftspdxsinhumanizedmice
AT chungyeunjun studyingcancerimmunotherapyusingpatientderivedxenograftspdxsinhumanizedmice
AT leecharles studyingcancerimmunotherapyusingpatientderivedxenograftspdxsinhumanizedmice

Ejemplares similares